RCUS
Arcus Biosciences, Inc.
NYSE · USHealthcareBiotechnology
$28.17+2.92%
Price as of Jul 20, 2026
RCUS profitability
Arcus Biosciences, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 97.0%
- EBITDA margin
- -139.8%
- EBIT margin
- -168.6%
- Net margin
- -156.4%
- Free cash flow margin
- -207.2%
Returns
- Return on equity
- -70.4%
- Return on assets
- -37.0%
- Return on invested capital
- -62.5%
- Asset turnover
- 0.22x
Cash efficiency
- Cash from operations
- -$488.0M
- Cash per share
- $6.54
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.